Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
10
2019
accepted:
05
03
2020
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
1
7
2020
Statut:
epublish
Résumé
The advent of new therapies has increased the need to achieve early diagnosis in Spinal Muscular Atrophy (SMA). The aim of the present study was to define the age of diagnosis in the three main types of SMA with pediatric-onset and the timing between the recognition of clinical signs and confirmed genetic diagnosis. All patients with a confirmed diagnosis of type I, II, III SMA followed in 5 Italian centers were included in this study, assessing age at symptoms onset, presenting sign or symptom, age at diagnosis, interval between clinical onset and diagnosis and type of medical investigations conducted in order to obtain the diagnosis. The cohort included 480 patients, 191 affected by SMA type I, 210 by type II and 79 by type III. The mean age at diagnosis was 4.70 months (SD ±2.82) in type I, 15.6 months (SD±5.88) in type II, and 4.34 years (SD±4.01) in type III. The mean time between symptom onset and diagnosis was 1.94 months (SD±1.84) in type I, 5.28 months (SD±4.68) in type II and 16.8 months (SD±18.72) in type III. Our results suggest that despite improved care recommendations there is still a marked diagnostic delay, especially in type III. At the time new therapies are becoming available more attention should be devoted to reducing such delay as there is consistent evidence of the benefit of early treatment.
Sections du résumé
BACKGROUND
The advent of new therapies has increased the need to achieve early diagnosis in Spinal Muscular Atrophy (SMA). The aim of the present study was to define the age of diagnosis in the three main types of SMA with pediatric-onset and the timing between the recognition of clinical signs and confirmed genetic diagnosis.
METHODS
All patients with a confirmed diagnosis of type I, II, III SMA followed in 5 Italian centers were included in this study, assessing age at symptoms onset, presenting sign or symptom, age at diagnosis, interval between clinical onset and diagnosis and type of medical investigations conducted in order to obtain the diagnosis.
RESULTS
The cohort included 480 patients, 191 affected by SMA type I, 210 by type II and 79 by type III. The mean age at diagnosis was 4.70 months (SD ±2.82) in type I, 15.6 months (SD±5.88) in type II, and 4.34 years (SD±4.01) in type III. The mean time between symptom onset and diagnosis was 1.94 months (SD±1.84) in type I, 5.28 months (SD±4.68) in type II and 16.8 months (SD±18.72) in type III.
CONCLUSIONS
Our results suggest that despite improved care recommendations there is still a marked diagnostic delay, especially in type III. At the time new therapies are becoming available more attention should be devoted to reducing such delay as there is consistent evidence of the benefit of early treatment.
Identifiants
pubmed: 32203538
doi: 10.1371/journal.pone.0230677
pii: PONE-D-19-28344
pmc: PMC7089564
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0230677Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Neuromuscul Disord. 2019 Nov;29(11):842-856
pubmed: 31704158
Pediatr Pulmonol. 2002 Jul;34(1):16-22
pubmed: 12112792
Science. 1994 Jun 3;264(5164):1474-7
pubmed: 7910982
Cell. 1995 Jan 13;80(1):1-5
pubmed: 7813005
Nature. 1990 Jun 28;345(6278):823-5
pubmed: 1972783
N Engl J Med. 2017 Nov 2;377(18):1723-1732
pubmed: 29091570
Pediatr Neurol. 2015 Oct;53(4):293-300
pubmed: 26260993
Neurology. 2014 Aug 26;83(9):810-7
pubmed: 25080519
Neuromuscul Disord. 1991;1(2):77-80
pubmed: 1845352
Lancet. 1995 Apr 15;345(8955):985-6
pubmed: 7715313
Eur J Hum Genet. 2015 May;23(5):575-80
pubmed: 25074464
Neuromuscul Disord. 2018 Feb;28(2):103-115
pubmed: 29290580
Orphanet J Rare Dis. 2011 Nov 02;6:71
pubmed: 22047105
PLoS One. 2012;7(4):e33572
pubmed: 22558076
Neurology. 2007 Nov 13;69(20):1931-6
pubmed: 17998484
Neuromuscul Disord. 2018 Jan;28(1):24-28
pubmed: 29174525
N Engl J Med. 2018 Feb 15;378(7):625-635
pubmed: 29443664
J Neurol Sci. 1997 Feb 27;146(1):67-72
pubmed: 9077498
J Pediatr. 2013 Jan;162(1):155-9
pubmed: 22809660
Neuromuscul Disord. 1992;2(5-6):423-8
pubmed: 1300191
Neuromuscul Disord. 2015 Jul;25(7):593-602
pubmed: 26045156
Cell. 1995 Jan 13;80(1):155-65
pubmed: 7813012
Lancet. 1980 Apr 26;1(8174):919-22
pubmed: 6103267
Neuromuscul Disord. 2018 Mar;28(3):197-207
pubmed: 29305137
Arch Neurol. 1995 May;52(5):518-23
pubmed: 7733848
Lancet Neurol. 2012 May;11(5):443-52
pubmed: 22516079
Ann Neurol. 2005 May;57(5):704-12
pubmed: 15852397